<DOC>
	<DOCNO>NCT02607306</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare efficacy safety insulin degludec/liraglutide , insulin degludec liraglutide Japanese subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Trial Comparing Efficacy Safety Insulin Degludec/Liraglutide , Insulin Degludec Liraglutide Japanese Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male female Japanese subject , age least 20 year time signing informed consent Type 2 diabetes subject ( diagnose clinically ) least 6 month prior screen HbA1c ( glycosylated haemoglobin ) 7.011.0 % ( inclusive ) central laboratory analysis , aim median 8.3 % . When approximately 50 % randomised subject HbA1c 8.3 % , remain subject randomise must HbA1c equal 8.3 % ; approximately 50 % randomised subject HbA1c equal 8.3 % , remain subject randomise must HbA1c 8.3 % Bodymass index ( BMI ) equal 20 kg/m^2 Subjects stable therapy one OAD ( define unchanged medication unchanged dose ) least 60 day ( metformin , aGI , TZD , SU , SGLT2i glinide ) prior screen accord approve Japanese label Previous treatment insulin ( except shortterm treatment connection intercurrent illness include gestational diabetes ) Treatment medication indication diabetes obesity state inclusion criterion period 60 day screen Anticipated initiation change concomitant medication excess 14 day know affect weight glucose metabolism Impaired liver function , define alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) equal 2.5 time upper limit normal Renal impairment estimate Glomerular Filtration Rate ( eGFR ) 60mL/min/1.73m^2 per Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) Screening calcitonin equal 50 ng/L History pancreatitis ( acute chronic ) Personal family history medullary thyroid carcinoma ( MTC ) multiple endocrine neoplasia type 2 ( MEN 2 ) Subjects presently classified New York Heart Association ( NYHA ) Class IV</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>